Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06960577
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Phase 2 · Australia, Brazil, Canada, Spain, France, Italy, Netherlands · 58 sites
Registry update: 8 Oct 2026
NCT06439836
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Phase 1 · United States · 11 sites
Registry update: 21 Sept 2026
NCT06983210
Recruiting
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Phase 2 · Japan · 1 site
Registry update: 14 Aug 2025
NCT06916494
Recruiting
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
Phase 1 · China · 1 site
Registry update: 10 Apr 2025
NCT06394869
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Not applicable · United States · 20 sites
Registry update: 2 Jul 2026
NCT06586255
Recruiting
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Phase 1 · United States · 1 site
Registry update: 14 May 2026
NCT06879145
Recruiting
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Phase 2/3 · China · 1 site
Registry update: 13 Jul 2026
NCT06704191
Recruiting
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Phase 1/2 · United States · 1 site
Registry update: 8 Oct 2026
NCT07339878
Recruiting
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Not applicable · France · 1 site
Registry update: 14 Jan 2026
NCT07782164
Recruiting
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Not applicable · Netherlands · 1 site
Registry update: 28 Aug 2026
NCT06943521
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 · Japan, United States · 6 sites
Registry update: 11 Dec 2025
NCT07647289
Recruiting
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · China · 1 site
Registry update: 15 Jun 2026
NCT07327489
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Not applicable · United States · 8 sites
Registry update: 29 Jun 2026
NCT06929286
Recruiting
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 3 · United States · 9 sites
Registry update: 20 Aug 2026
NCT06809140
Recruiting
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Phase 2 · United States · 5 sites
Registry update: 5 Aug 2026
NCT07721935
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
Not applicable · China · 3 sites
Registry update: 23 Jul 2026
NCT06470282
Recruiting
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Phase 1/2 · United States · 1 site
Registry update: 1 Oct 2026
NCT06926374
Recruiting
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Not applicable · China · 1 site
Registry update: 16 Apr 2025
NCT06529822
Recruiting
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Phase 1 · United States · 3 sites
Registry update: 21 Sept 2026
NCT06493552
Recruiting
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2/3 · United States · 1 site
Registry update: 3 Apr 2025

Ordered by registry start date. Freshness and sponsorship never change the order.